

Word count 1487

A Promise Unfulfilled : The use of Mineralocorticoid Receptor Antagonists (MRAs) in patients with Heart Failure and a Reduced Left Ventricular Ejection Fraction .

Bertram Pitt MD * ,Murray Epstein MD **

*-University of Michigan School of Medicine, **-University of Miami Miller School School of Medicine

The steroidal mineralocorticoid receptor antagonists (MRAs) , reduce mortality and hospitalizations for heart failure (HFrEF) in patients with heart failure and a reduced left ventricular ejection fraction (HFrEF) . Their incorporation into US and European guidelines as a class 1 indication for HFrEF held the promise for a substantial reduction in CV mortality , HFrEFs, and consequentially health care costs . It is therefore discouraging to observe that despite a class 1 indication in guidelines over several years their use remains suboptimal in comparison to the other major guideline recommended therapies for HFrEF .

In this issue of the Journal Zahir et al (1) report upon the temporal trends in initiation and subsequent withdrawal of a MRA from a nation wide study of 51,512 patients with HFrEF in Denmark from 2003-2017 . They found that only 40.% of patients initiated a MRA within 6 months of their HF diagnosis . Furthermore , the use of a MRA did not increase significantly over the past decade . In those in whom a MRA was initiated 49% of patients discontinued them and only 40% of these patients restarted them . The suboptimal use of MRAs in patients with HFrEF in Denmark (1) is unfortunately not unique. The US Get with the Guidelines Heart Failure Registry (GWTG-HF) (2) also found that the use of MRAs in patients with HFrEF was suboptimal , even in patients with normal renal function in whom the risk of inducing hyperkalemia (HK) is minimal . In view of the widespread underutilization of MRAs and their poor persistence in patients with HFrEF (1,2) despite evidence of their benefit and repeated recommendations in guidelines it is highly unlikely that further reemphasis and dissemination of guidelines will remedy the situation .Consequently we propose that the time has come to implement bold disruptive steps that will change the future trajectory of MRA use in HFrEF .

The failure to initiate and to remain on a MRA once initiated is in part due to the fear of inducing HK and or exacerbating renal dysfunction and therefore the need to serially monitor serum potassium (K+) and renal function . In many part of the world the majority of patients with HF are cared for by family physicians or internists, who are often overwhelmed and do not have either the time or economic incentives to monitor serum K+ or renal function and to discontinue or adjust the dose of the MRA if required. Consequently the path of least resistance is not to administer a MRA . Regretfully negative consequences are incurred since while avoiding the necessity and costs of monitoring K+ and renal function the failure to initiate and to persist on a MRA in a patient with HFrEF is associated with an unacceptable increase in CV mortality (3) . In the Danish (1) and GWTG-HF (2) studies the major reason for discontinuing a MRA once initiated however was not an increase in K+ but rather a decrease in renal function . :

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ejhf.2441

This article is protected by copyright. All rights reserved.

Constructive Proposals to Increase the Use of MRAs in Patients with HFrEF :

1-Introduction of a MRA in hospital or soon after an episode of HFrEF

There is increasing evidence that after hemodynamic stabilization and the use of iv diuretic therapy that guideline recommended HF therapies can be safely initiated prior to hospital discharge or shortly afterwards (3-4). The hospital team caring for HF patients has the best opportunity to initiate guideline recommended therapy for HF. In contrast after discharge there is often a gap of several weeks before the patient is seen in follow-up and often a change in the physician responsible for the care of the patient . The Danish (1) and GWTG-HF (2) registries suggest that MRAs are not being initiated prior to hospital discharge or soon thereafter in most medical centers. If they are not initiated in hospital it is likely that they will not be initiated at follow up.

2- The use of a non-steroidal MRA:

Recent evidence suggests that the use of the non-steroidal MRA finerenone , recently approved by the US FDA for patients with diabetic nephropathy , prevents the progression of renal disease and reduce cardiovascular (CV) outcomes , mainly HFH , in patients with diabetic nephropathy with approximately a 1% discontinuation rate due to HK (5,6).In contrast to spironolactone finerenone has a shorter half life, a different mode of binding to the MR and a more favorable distribution between the heart and kidney (7) . While It has recently been suggested (8) that the incidence of HK incurred with finerenone in the “real world” will be similar to the incidence of HK associated with spironolactone noted by Jurlink et al (9) there is evidence from a head to head comparison in patients with HFrEF that finerenone 5-10 mg/day ,at a similar reduction in NT-proBNP , is associated with a lower incidence of HK than spironolactone 25-50 mg/day (10) . What is often unappreciated, but plainly clear , is that the incidence of HK noted by Jurlink et al (9) promoted by spironolactone was confounded by the absence of both preselection of patients or mitigation strategies . In contrast adherence by clinicians to recent guidelines and the selection of a non-steroidal MRA should diminish this risk .

3- While fewer episodes of HK are likely with the non steroidal than the steroidal MRAs, when HK is encountered or anticipated, such as in patients with an eGFR < 45 ml/min/1.73m² , the new potassium binders such as patiromer or SZC , both of which have enabled sustained normokalaemia for at least a year in patients on a MRA (11) , can be administered . While the cost of the novel potassium binders has been invoked to limit their use a recent propensity matched study of patients with a K⁺ > 5.0 mmol/l either receiving or not receiving patiromer found that the use of patiromer was associated with a reduction

in both hospitalizations and Emergency Room encounters associated with a significant reduction in costs (12).

4- The combination of a MRA and a SGLT2i

There is evidence from a preclinical model of hypertension -induced cardiorenal disease that a low dose combination of finerenone and the SGLT2i empagliflozin are additive in reducing mortality (13). It can therefore be postulated that in the future the use and persistence of MRAs in patients with HFrEF might be enhanced by the concomitant use of a SGLT2i .

5- New incentives for prescribing MRAs in HFrEF .

Barriers for implementing and sustaining MRA use should be identified and overcome . These barriers include an incomplete knowledge of current guidelines and the reluctance of many family physicians and internists to undertake the burden and costs of serial monitoring serum K⁺ and renal function . Consequently there is an urgent need to adopt new quality measures and economic incentives to enhance the use and persistence of MRAs . An example of the role of incentives is the successful introduction and adoption of pay-for-performance indicators, screening for urinary albuminuria in the United Kingdom resulted in a increase in screening to > 80% (14) . When the QOF indicator incentivizing the recording of urine albumin : creatinine ratio (uACR) was discontinued from April 2014, the percentage of people receiving this care process has since decreased considerably (15)

In summary , we propose a series of next steps that hold the promise of closing the gap between the promise of guideline directed MRA therapy in patients with HFrEF and their suboptimal utilization .Initiation of a MRA in hospital prior to discharge after an episode of HFrEF; use of a non steroidal MRA, such as finerenone , alone or in conjunction with a SGLT2i ; if necessary the addition of a potassium binder ; as well as new quality metrics and economic incentives to implement guideline recommendations for MRA use collectively hold the promise that the reduction in CV outcomes originally suggested by the approval of MRAs for HFrEF will eventually be realized . It will however be necessary to perform further adequately powered prospective randomized and comparative studies evaluating the efficacy and safety of these strategies before the full potential of MRAs to reduce CV mortality, HFrEF and therefore health care costs can be realized .While the search for new drugs , devices and strategies to further reduce CV outcomes in patients with HFrEF is important, efforts to increase the initiation and persistence of existing therapies, such as MRAs , are as or more important and more cost

effective . It is therefore imperative that the proposals outlined above be evaluated in rigorous prospective studies and if successful rapidly implemented .

REFERENCES

1. Zahir D., Bonde A., Madelaire C. et al . Temporal Trends in Initiation of Mineralocorticoid Receptor Antagonists and Risk of Subsequent Withdrawal in Patients with Heart Failure : A Nationwide study in Denmark from 2003-2017. *Eur J HF* (2022)
2. Patel R.B. et al Kidney Function and Outcomes in Patients Hospitalized with Heart Failure . *J.Am. Coll. Cardiol* 78; 33-0343 (2021)
3. Bhaat D. L> , Szarek M., Steg P.G. , et al . Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure . *New Eng J Med.* 384:117-128 (2021)
4. Butler J. , Anstrom K. , Felker M. et al . Efficacy and Safety of Spironolactone in Acute Heart Failure *JAMA Cardiol* 9: 950-958 (2017)
5. Pitt B. Fillipatos G. Agarwal R. et al . Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. *N Engl . J Med* 385:2252-2263 (2021)
6. Bakris G. L. , Agarwal R. , Anker S. , et al . Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *N Engl. J . Med* 383:2219-2229 (2020)
7. Epstein, M. Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: From Hans Selye to the present. *Am J Nephrol.* 2021 Apr 15:1-8. Doi: 10.1159/000515622. Epub ahead of print. PMID: 338579
8. Moura-Neto JA, Ronco C; The RALES Legacy and Finerenone Use on CKD Patients. *Clin J Am Soc Nephrol.* Sep;16(9):1432-1434, 2021. Doi: 10.2215/CJN.02150221 Epub 2021 Aug 6, 2021. PMID: 34362811
9. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA:. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. *N Engl J Med.* Aug 5;351(6):543-51, 2004. Doi: 10.1056/NEJMoa040135 PMID: 15295047

10. Pitt B, Kober L, Ponikowski P, Gheorghide M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim S-Y, Zannad F: Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. *Eur Heart J.* 34(31):2453-2463, 2013. Doi:10.1093/eurheartj/eh187
11. Rossignol, Patrick, et al. "Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared With Data From the Clinical Trial Program." *Drugs – Real World Outcomes*, vol. 8, no. 3, 2021, pp. 315-323.
12. Nihar R. Desai, Paula J. Alvarez, Ladan Golestaneh, Steven D. Woods, Steven G. Coca & Christopher G. Rowan (2021) Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients, *Journal of Medical Economics*, 24:1, 1025-1036, DOI: 10.1080/13696998.2021.1965389
13. Kolkhof P, Hartmann E, Freyberger A, Pavkovic M, Mathar I, Sandner P, Droebner K, Joseph A, Hüser J, Eitner F. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. *Am J Nephrol.* 2021;52(8):642-652. doi: 10.1159/000516213. Epub 2021 Jun 10. PMID: 34111864; PMCID: PMC8619789.
14. Diabetes-UK. Position statement: The Future of the Quality and Outcomes Framework in England 2018. Accessed January 7th 2022
15. Data for 2009-10 until 2014-15 taken from NHS Digital (2016) National Diabetes Audit – 2013-14 and 2014-15: Report 1, Care Processes and Treatment Targets; data for 2015-16 from NHS Digital (2017) National Diabetes Audit, 2015-16 Report 1: Care Processes and Treatment Targets; data for 2016-17 from NHS Digital (2017) National Diabetes Audit Report 1 Care Processes and Treatment Targets 2016-17. Accessed January 7, 2022

Author Manuscript